Bouali Y, Donal E, Gallard A, et al. - In this study with prospectively included 79 patients with heart failure with reduced ejection fraction (HFrEF) (mean age: 66 ± 12 years; LV ejection fraction: 28 ± 9%), researchers assessed the short as well as medium term effect of Sacubitril/Valsartan treatment on myocardial work (MW) parameters. They also focused on the prognostic value of MW in this patient population. Findings revealed that a significant improvement of myocardial constructive work (CW) and work efficiency was brought about by Sacubitril/Valsartan in patients with HFrEF who received a comprehensive background beta-blocker and mineral-corticoid receptor antagonist therapy. MACEs (cardiovascular events) occurrence among the participants was predicted by the estimation of CW prior to the start of Sacubitril/Valsartan.